Wird geladen...

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life

Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Planas, Raquel, Martin, Roland, Sospedra, Mireia
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2014
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3983075/
https://ncbi.nlm.nih.gov/pubmed/24741337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PROM.S41768
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!